Replimune Group, INC

Replimune Group, Inc. presented data on RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma to the FDA's Advisory Committee.

Replimune Group announced fiscal year 2026 financial results and provided corporate updates, including the FDA's acceptance of the BLA resubmission for RP1 in advanced melanoma with a target action date of August 2, 2026.

The FDA has accepted Replimune's resubmitted Biologics License Application for RP1 in advanced melanoma with a goal date of August 2, 2026.

Replimune Group, Inc. announced it will resubmit its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma following productive FDA discussions.

Replimune Group, Inc. announced an amendment to its loan agreement with Hercules Capital, extended its cash runway, and reported fiscal third quarter 2026 financial results while awaiting an FDA decision on RP1 for advanced melanoma.

Replimune Group, Inc. provides an updated corporate presentation highlighting recent business and strategic developments, positive clinical data for RP1 and RP2, and readiness for commercial launch.

Replimune Group, Inc. reported increased net losses and R&D expenses in its latest quarterly filing, while navigating a resubmitted BLA for RP1 and extending its debt maturity.

Replimune Group, Inc. reported increased net losses and significant R&D expenses in its latest quarterly filing, while navigating an FDA Complete Response Letter for its lead candidate RP1 and facing multiple legal and regulatory investigations.

Replimune Group, Inc. announced a Complete Response Letter from the FDA for its lead cancer immunotherapy, RP1, signaling significant delays and potential strategic shifts.

Replimune Group announces its financial results for the quarter ended December 31, 2024, and provides an update on its clinical programs, including the FDA's acceptance and priority review of the BLA for RP1 in combination with nivolumab.

Replimune Group, Inc. announces positive results from its IGNYTE trial and progress towards a BLA submission for RP1 in anti-PD1 failed melanoma.

Replimune Group reports a net loss of $53.8 million for the first quarter of fiscal year 2025, while advancing its oncolytic immunotherapy pipeline.

Replimune Group Inc. filed a Form 10-K detailing its capital stock, including common stock and preferred stock, and outstanding pre-funded warrants.

Replimune Group outlines its capital stock composition, including common and preferred shares, pre-funded warrants, and provisions designed to deter unsolicited acquisitions in its recent 10-K filing.

Replimune Group, Inc. files its annual report on Form 10-K, highlighting clinical trial progress, manufacturing updates, and strategic collaborations for its oncolytic immunotherapy pipeline.

Replimune Group Chief Commercial Officer Christopher Sarchi sold 12,000 shares of common stock at a weighted average price of $9.24.

Konstantinos Xynos, Chief Medical Officer at Replimune Group, Inc., sold 14,023 shares of common stock to cover tax withholding obligations related to Restricted Stock Units.

Replimune Group Inc. Chief Accounting Officer Andrew Schwendenman sold 7,894 shares of common stock to cover tax obligations related to RSU vesting.

Replimune Group Inc. reports a Form 4 filing detailing a transaction by Chief Commercial Officer Christopher Sarchi involving the sale of common stock to cover tax withholding obligations.

Philip Astley-Sparke, a Director at Replimune Group, Inc., reported a transaction involving the sale of 17,657 shares of common stock to cover tax withholding obligations.

Replimune Group Inc. CEO Sushil Patel sold 37,324 shares of common stock to cover tax withholding obligations related to RSU vesting.

Replimune Group, Inc. has issued a definitive additional materials filing providing notice and details for its 2025 Annual Meeting of Stockholders, including proposals for director elections, auditor ratification, executive compensation, and an incentive plan amendment.

Replimune Group, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on September 3, 2025, seeking approval for director elections, auditor ratification, executive compensation, and an amendment to its incentive compensation plan.

Replimune Group, Inc. will hold its annual meeting of stockholders virtually on September 4, 2024, to vote on director elections, auditor ratification, and executive compensation.

Replimune Group will hold its 2024 Annual Meeting of Stockholders virtually on September 4, 2024, to vote on director elections, auditor ratification, executive compensation, and the frequency of advisory votes on executive pay.

Baker Bros. Advisors LP and its affiliates have increased their beneficial ownership in Replimune Group, Inc. to 14.3% and secured a board seat with the appointment of Michael Goller.

Ridgeback Capital Investments has filed a Schedule 13G reporting a 7.6% beneficial ownership stake in Replimune Group, Inc.

RTW Investments, LP and Roderick Wong report beneficial ownership of 8.9% of Replimune Group, Inc. common stock as of March 31, 2026.

Suvretta Capital Management, LLC and Aaron Cowen have filed a Schedule 13G reporting a 5.1% beneficial ownership stake in Replimune Group, Inc.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 0.2% of Replimune Group Inc.'s common stock as of April 30, 2026.

Forbion Capital Fund III and Forbion III Management B.V. have reduced their beneficial ownership in Replimune Group, Inc. to 3.5% of outstanding common stock.

Redmile Group, LLC and its principal, Jeremy C. Green, reported a 0.7% beneficial ownership stake in Replimune Group, Inc., holding 535,818 shares as of September 30, 2025.